U.S. FDA panel narrowly backs Cempra's antibiotic solithromycin

(Reuters) - The benefit of Cempra Inc's antibiotic to treat community-acquired pneumonia outweighs the risk of liver injury, an advisory panel to the U.S. Food and Drug Administration narrowly concluded on Friday.